Demant has raised its guidance for 2021 based on looking back on the first three months, rather than ahead to the next nine, says Søren Nielsen, CEO of Demant, to MedWatch.
“We are right on track, if not a little ahead of schedule, and that of course gives us reason to believe that our plans for the rest of the year are intact and realistic. Raising our expectations for the year is therefore primarily related to the time that has passed and not a change in terms of what lies ahead of us,” he says.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.